Active control trials for epilepsy: Avoiding bias in head-to-head trials

Neurology

Volumn 66, Issue 9, 2006, Pages 1294-1295

  French, Jacqueline A ^a   Kryscio, Richard J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; OXCARBAZEPINE; PLACEBO;

DRUG EFFICACY; EDITORIAL; EPILEPSY; HUMAN; MIGRAINE; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME;

ANTICONVULSANTS; BIAS (EPIDEMIOLOGY); CARBAMAZEPINE; CONTROL GROUPS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; EPILEPSY, GENERALIZED; EUROPEAN UNION; HUMANS; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SODIUM CHANNEL BLOCKERS; TREATMENT OUTCOME; TRIAZINES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33646672000     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000218836.23697.f9     Document Type: Editorial

References (6)

1. Sachdeo R, Edwards K, Hasegawa H, et al. Safety and efficacy of oxcarbazepine 1200 mg/day in patients with recent onset partial epilepsy. Neurology 1999;52:391.
2. Gamble C, Williamson PR, Chadwick DW, Marson AG. A meta-analysis of individual patient responses to lamotrigine or carbaniazepine monotherapy. Neurology 2006;66:1310-1317.
3. Ferrendelli JA. Concerns with antiepileptic drug initiation: safety, tolerability, and efficacy. Epilepsia 2001;42 Suppl 4:28-30.
4. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995;345: 476-479.
5. Benbadis SR, Tatum WOT, Gieron M. Idiopathic generalized epilepsy and choice of antiepileptic drugs. Neurology 2003;61:1793-1795.
6. Meinert CL. Clinical trials: design, conduct, and analysis. New York: Oxford; 1986: 66.